310 results on '"La Mura, Vincenzo"'
Search Results
2. Comprehensive investigation of platelet function in patients with cirrhosis
3. Evolution of spontaneous portosystemic shunts over time and following aetiological intervention in patients with cirrhosis
4. Liver-related aspects of valoctocogene roxaparvovec gene therapy for hemophilia A: expert guidance for clinical practice
5. Gene therapy for people with hemophilia B: a proposed care delivery model in Italy
6. Predicting survival in patients with ‘non-high-risk’ acute variceal bleeding receiving β-blockers+ligation to prevent re-bleeding
7. Residual burden of liver disease after HCV clearance in hemophilia: a word of caution in the era of gene therapy
8. Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: The IMPORTAL competing-risk meta-analysis
9. Preventing Further Decompensation: Consensus Statements of Panel 7
10. Prevention of Variceal Bleeding and Rebleeding
11. TOP-301 Impact of clonal hematopoiesis of indeterminate potential on hepatocellular carcinoma in steatotic liver disease
12. Clinical and genetic determinants of the fatty liver–coagulation balance interplay in individuals with metabolic dysfunction
13. External validation of risk scores to predict in-hospital mortality in patients hospitalized due to coronavirus disease 2019
14. Case 3: Congestive Hepatopathy with High Liver and Spleen Stiffness in a 17 Years Old Male Patient
15. Liver Transplantation for Porto-Sinusoidal Vascular Liver Disorder: Long-term Outcome
16. Management of Ascites
17. Peritoneal Fluid Analysis
18. Portal Hypertension and Ascites: Patient-and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (AISF)
19. Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data
20. Deep vein thrombosis in COVID-19 patients in general wards: prevalence and association with clinical and laboratory variables
21. The Role of Spleen and Liver Elastography and Color-Doppler Ultrasound in the Assessment of Transjugular Intrahepatic Portosystemic Shunt Function
22. Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis
23. Predicting survival in patients with ‘non-high-risk’ acute variceal bleeding receiving β-blockers+ligation to prevent re-bleeding
24. Correction to: Usefulness of Fibrosis-4 (FIB-4) score and metabolic alterations in the prediction of SARS-CoV-2 severity
25. Evaluation of three “beyond Baveno VI” criteria to safely spare endoscopies in compensated advanced chronic liver disease
26. To be or NOD 2 be: The role of NOD2 in predisposing patients with cirrhosis towards infections
27. Splanchnic vein thrombosis associated with SARS-CoV-2 infection: a VALDIG case-control study
28. Harmful and Beneficial Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis
29. Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis
30. Porto sinusoidal vascular liver disorder: natural history and long-term outcome
31. Recent splanchnic vein thrombosis occurring during Sars-Cov-2 infection-The VALDIG study
32. Is non-alcoholic fatty liver disease a prothrombotic risk factor?
33. Carvedilol as the new non‐selective beta‐blocker of choice in patients with cirrhosis and portal hypertension
34. Consensus Statements: Changing Scenarios: Prevention of Decompensation
35. Role of Comorbidities in the General Management of Compensated Cirrhosis, Including Malnutrition
36. Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: The IMPORTAL competing-risk meta-analysis
37. Improving Management of Portal Hypertension: The Potential Benefit of Non-Etiological Therapies in Cirrhosis
38. Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference
39. A pragmatic strategy for the screening and treatment of portal hypertension in patients needing systemic treatment for advanced hepatocellular carcinoma.
40. Corrigendum to ‘External validation of risk scores to predict in-hospital mortality in patients hospitalized due to coronavirus disease 2019’
41. Liver Health in Patients with Hemophilia: Residual Risk Factors of Liver-Related Complications after HCV Clearance
42. Rational hemostatic management in cirrhosis: from old paradigms to new clinical challenges
43. THU-295 - Recent splanchnic vein thrombosis occurring during Sars-Cov-2 infection-The VALDIG study
44. Corrigendum to ‘Baveno VII – Renewing consensus in portal hypertension’ [J Hepatol (2022) 959-974]
45. Baveno VII – Renewing consensus in portal hypertension
46. Reply to the diagnostic conundrum of bacterial infections in cirrhotic patients.
47. The impact of infection by multidrug‐resistant agents in patients with cirrhosis. A multicenter prospective study
48. Patients Whose First Episode of Bleeding Occurs While Taking a β-Blocker Have High Long-term Risks of Rebleeding and Death
49. Simvastatin Prevents Liver Microthrombosis and Sepsis Induced Coagulopathy in a Rat Model of Endotoxemia
50. Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.